CLINICAL_TRIALS
trial_result
· 2014-03-19
Clinical Trial Update: A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO) [Phase 3]
Summary
Completed Phase 3 trial evaluating the safety of omalizumab (Xolair) in patients with moderate to severe persistent asthma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Asthma | Phase 3 | Status: COMPLETED